125 related articles for article (PubMed ID: 12242732)
21. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
22. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure.
Kaplan SA; Te AE; Pressler LB; Olsson CA
J Urol; 1995 Nov; 154(5):1764-9. PubMed ID: 7563342
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia].
Sakai S; Shimazaki J
Nihon Hinyokika Gakkai Zasshi; 1996 Mar; 87(3):695-701. PubMed ID: 8709447
[TBL] [Abstract][Full Text] [Related]
24. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction.
Berger AP; Deibl M; Leonhartsberger N; Bektic J; Horninger W; Fritsche G; Steiner H; Pelzer AE; Bartsch G; Frauscher F
BJU Int; 2005 Nov; 96(7):1073-8. PubMed ID: 16225531
[TBL] [Abstract][Full Text] [Related]
25. Predicted and actual change in serum PSA following prostatectomy for BPH.
Lloyd SN; Collins GN; McKelvie GB; Hehir M; Rogers AC
Urology; 1994 Apr; 43(4):472-9. PubMed ID: 7512298
[TBL] [Abstract][Full Text] [Related]
26. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
[TBL] [Abstract][Full Text] [Related]
27. Three-dimensional ultrasonography in evaluation of benign prostatic hyperplasia.
Kanao K; Kikuchi E; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Int J Urol; 2004 Dec; 11(12):1087-91. PubMed ID: 15663680
[TBL] [Abstract][Full Text] [Related]
28. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
29. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia.
Kurita Y; Masuda H; Terada H; Suzuki K; Fujita K
Urology; 1998 Apr; 51(4):595-600. PubMed ID: 9586613
[TBL] [Abstract][Full Text] [Related]
30. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
31. Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy.
Ajayi I; Aremu A; Olajide A; Bello T; Olajide F; Adetiloye V
Pan Afr Med J; 2013; 16():149. PubMed ID: 24876907
[TBL] [Abstract][Full Text] [Related]
32. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Hammerer PG; McNeal JE; Stamey TA
J Urol; 1995 Jan; 153(1):111-4. PubMed ID: 7526003
[TBL] [Abstract][Full Text] [Related]
33. [Results of studies of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hypertrophy and prostatic cancer].
Romics I; Bodrogi I; Frang D
Orv Hetil; 1995 Jul; 136(30):1599-602. PubMed ID: 7543669
[TBL] [Abstract][Full Text] [Related]
34. Measuring resistance index in patients with BPH and lower urinary tract symptoms.
Ozdemir H; Onur R; Bozgeyik Z; Orhan I; Ogras MS; Ogur E
J Clin Ultrasound; 2005 May; 33(4):176-80. PubMed ID: 15856514
[TBL] [Abstract][Full Text] [Related]
35. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
[TBL] [Abstract][Full Text] [Related]
36. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens.
Robert M; Costa P; Bressolle F; Mottet N; Navratil H
Br J Urol; 1995 Mar; 75(3):317-24. PubMed ID: 7537601
[TBL] [Abstract][Full Text] [Related]
37. The importance of measuring the prostatic transition zone: an anatomical and radiological study.
Zlotta AR; Djavan B; Damoun M; Roumeguere T; Petein M; Entezari K; Marberger M; Schulman CC
BJU Int; 1999 Oct; 84(6):661-6. PubMed ID: 10510112
[TBL] [Abstract][Full Text] [Related]
38. Measurement of PSA density by 3 imaging modalities and its correlation with the PSA density of radical prostatectomy specimen.
Varkarakis I; Zarkadoulias A; Bourdoumis A; Chatzidarellis E; Antoniou N; Deliveliotis C
Urol Oncol; 2013 Oct; 31(7):1038-42. PubMed ID: 22196747
[TBL] [Abstract][Full Text] [Related]
39. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
[TBL] [Abstract][Full Text] [Related]
40. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
